SEC Form 4 · accession 0001933414-26-000118
Mineralys Therapeutics, Inc. · MLYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Malcom Rodman
Officer — Chief Medical Officer
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 7:33 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001933414
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2026 | M | 2,170 | $16.00 | A | 53,554 | D | |
| Common Stock | Aug 10, 2026 | S | 2,170 | $27.09 | D | 51,384 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2 | $16.00 | Aug 10, 2026 | M | 2,170 | D | — | Feb 9, 2033 | Common Stock | 2,170 | 13,024 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
- F2The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.